Research never stops

EVT Innovate

EVT Innovate “Cure X  and Target X -Initiatives” mark a globally unique paradigm that will link a network of academic innovation with our vision of a more integrated and increasingly industrialised drug discovery infrastructure that incorporates the best from academia, biotech and Pharma to deliver innovative drugs to the pharmaceutical industry and patients

Evotec is one of the few drug discovery businesses that can execute a comprehensive outsourcing strategy and represents the most comprehensive and systematic integrated drug discovery process for drug targets in Evotec’s key areas of expertise, including metabolic disease, pain, oncology and CNS.

Evotec is committed to delivering solutions for some of the largest and most pressing global medical needs. With EVT Innovate, the Company brings forward the most promising scientific ideas to make a difference in key medical areas. In its research initiatives, Evotec is progressing its pre-clinical assets to potential entry points for drug discovery alliances and partners those to pharmaceutical companies for upfront payments, on-going research fees and significant milestones and royalties. Through this strategy, Evotec is building a pipeline without bearing the extensive financial risk normally involved in such projects.

EVT Innovate

Anti-infectives

- read more

Diabetes

- read more

Neurology

- read more

Oncology

- read more

Pain and inflammation

- read more

Topas Therapeutics GmbH

- read more

Oxford / LAB282

- read more

Yale/Open innovation

- read more